Ionis Pharmaceuticals (NASDAQ: IONS) insider plans 5,885-share sale

Rhea-AI Filing Summary

Ionis Pharmaceuticals reported a planned sale of 5,885 shares of its common stock under Rule 144. The shares, with an aggregate market value of $487,897.77, are expected to be sold on or about January 30, 2026 through Morgan Stanley Smith Barney on NASDAQ.

The seller acquired these 5,885 shares on January 29, 2026 via performance stock units granted under the company’s 2011 Equity Incentive Plan as compensation. During the prior three months, 8,977 Ionis common shares were also sold, generating gross proceeds of $674,621.55.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney 1585 Broadway New York NY 10036	5885	487897.77	161137930	01/30/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/29/2026	PSUs granted under 2011 Equity Incentive Plan	Ionis Pharmaceuticals			5885	01/29/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Morgan Stanley Smith Barney 1585 Broadway New York NY 10036	Common Stock	01/16/2026	8977	674621.55

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Ionis (IONS) Rule 144 filing disclose?

The filing discloses a planned sale of 5,885 Ionis Pharmaceuticals common shares under Rule 144. These shares were recently acquired as equity compensation and will be sold through Morgan Stanley Smith Barney on NASDAQ, providing transparency into insider-related share sales activity.

How many Ionis Pharmaceuticals (IONS) shares are being sold in this notice?

The notice covers a planned sale of 5,885 Ionis Pharmaceuticals common shares. The aggregate market value for this block is reported as $487,897.77, and the shares are expected to be sold on or about January 30, 2026 via NASDAQ through Morgan Stanley Smith Barney.

How were the Ionis (IONS) shares in the Rule 144 filing acquired?

The 5,885 Ionis Pharmaceuticals shares were acquired on January 29, 2026 through performance stock units granted under the company’s 2011 Equity Incentive Plan. The filing labels the nature of payment as compensation, indicating these shares were earned rather than bought with cash.

What recent Ionis (IONS) share sales are disclosed for the past 3 months?

The filing reports that 8,977 Ionis Pharmaceuticals common shares were sold on January 16, 2026. These earlier sales generated gross proceeds of $674,621.55, providing context for the seller’s recent trading activity alongside the newly planned 5,885-share Rule 144 sale.

Which broker and exchange are used in the Ionis (IONS) Rule 144 sale?

The filing lists Morgan Stanley Smith Barney, located at 1585 Broadway, New York, NY 10036, as the broker handling the trade. The planned sale of 5,885 Ionis Pharmaceuticals common shares is expected to take place on the NASDAQ stock market.